153 related articles for article (PubMed ID: 17433276)
21. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
23. T-cell distribution and adhesion receptor expression in metastatic melanoma.
Weishaupt C; Munoz KN; Buzney E; Kupper TS; Fuhlbrigge RC
Clin Cancer Res; 2007 May; 13(9):2549-56. PubMed ID: 17473183
[TBL] [Abstract][Full Text] [Related]
24. Marker utility for combination therapy.
Simeone E; Grimaldi AM; Ascierto PA
Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
[TBL] [Abstract][Full Text] [Related]
25. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
27. Reviewing the somatic genetics of melanoma: from current to future analytical approaches.
Dutton-Regester K; Hayward NK
Pigment Cell Melanoma Res; 2012 Mar; 25(2):144-54. PubMed ID: 22248438
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.
Eberle J; Fecker LF; Hossini AM; Kurbanov BM; Fechner H
Exp Dermatol; 2008 Jan; 17(1):1-11. PubMed ID: 18095940
[TBL] [Abstract][Full Text] [Related]
29. [Gene therapy in malignant melanoma. Interview with D. Schadendorf].
Schadendorf D
Hautarzt; 1996 Dec; 47(12):962-4. PubMed ID: 9081947
[No Abstract] [Full Text] [Related]
30. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Lorigan P; Eisen T; Hauschild A
Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
[TBL] [Abstract][Full Text] [Related]
31. From integrated genomics to tumor lineage dependency.
Garraway LA; Sellers WR
Cancer Res; 2006 Mar; 66(5):2506-8. PubMed ID: 16510564
[TBL] [Abstract][Full Text] [Related]
32. NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression.
Kim A; Yang Y; Lee MS; Yoo YD; Lee HG; Lim JS
Pigment Cell Melanoma Res; 2008 Dec; 21(6):653-64. PubMed ID: 19067970
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
36. Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers.
Bertucci F; Pages C; Finetti P; Rochaix P; Lamant L; Devilard E; Nguyen C; Houlgatte R; Birnbaum D; Xerri L; Brousset P
Anticancer Res; 2007; 27(5A):3441-9. PubMed ID: 17970093
[TBL] [Abstract][Full Text] [Related]
37. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas.
Dynek JN; Chan SM; Liu J; Zha J; Fairbrother WJ; Vucic D
Cancer Res; 2008 May; 68(9):3124-32. PubMed ID: 18451137
[TBL] [Abstract][Full Text] [Related]
38. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
[TBL] [Abstract][Full Text] [Related]
39. Molecular and genetic mechanisms in melanoma.
Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E
Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma: genetics and therapeutics in the genomic era.
Chin L; Garraway LA; Fisher DE
Genes Dev; 2006 Aug; 20(16):2149-82. PubMed ID: 16912270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
